Androgen receptor phosphorylation: Biological context and functional consequences

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  Koryakina, Yulia ^a   Ta, Huy Q ^a   Gioeli, Daniel ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Androgen receptor; Cell signaling; Gene transcription; Growth factor; Prostate

Indexed keywords

ACTIVATED CDC42 ASSOCIATED KINASE; ANDROGEN RECEPTOR; CHEMOKINE RECEPTOR CXCR; CYCLIN DEPENDENT KINASE; ENDOTHELIAL TYROSINE KINASE; HEMATOLOGICAL AND NEUROLOGICAL EXPRESSED 1; PROTEIN; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SERINE; THREONINE; TYROSINE; UNCLASSIFIED DRUG; PROTEIN KINASE;

BREAST CANCER; CLINICAL EFFECTIVENESS; COMPLETE ANDROGEN INSENSITIVITY SYNDROME; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SPINAL MUSCULAR ATROPHY; STAINING; ANIMAL; CHEMISTRY; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

ANIMALS; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN;

EID: 84905963848     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0472     Document Type: Review

References (97)

1. Aarnisalo P, Palvimo JJ & Janne OA 1998 CREB-binding protein in androgen receptor-mediated signaling. PNAS 95 2122-2127. (doi:10.1073/pnas.95.5. 2122)
2. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M & Koskinen PJ 2004 Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Letters 571 43-49. (doi:10.1016/j.febslet.2004.06.050)
3. Al-Dhaheri MH & Rowan BG 2006 Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor? Nuclear Receptor Signaling 4 e007. (doi:10.1621/nrs.04007)
4. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB et al. 2013 Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncology 14 1307-1316. (doi:10.1016/S1470-2045(13)70479-0)
5. Askew EB, Bai S, Blackwelder AJ & Wilson EM 2010 Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. Journal of Biological Chemistry 285 21824-21836. (doi:10.1074/jbc.M110.120600)
6. Bai S, He B & Wilson EM 2005 Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Molecular and Cellular Biology 25 1238-1257. (doi:10.1128/MCB.25.4.1238-1257. 2005)
7. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al. 2011 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery 1 487-495. (doi:10.1158/2159-8290.CD-11-0130)
8. Brumbaugh K, Johnson W, Liao W-C, Lin M-S, Houchins JP, Cooper J, Stoesz S & Campos-Gonzalez R 2011 Overview of the generation, validation, and application of phosphosite-specific antibodies. Methods in Molecular Biology 717 3-43. (doi: 10.1007/978-1-61779-024-9-1)
9. Bubulya A, Wise SC, Shen XQ & Burmeister LA 1996 c-Jun can mediate androgen receptor-induced transactivation. Journal of Biological Chemistry 271 24583-24589. (doi:10.1074/jbc.271.40.24583)
10. Bubulya A, Zhou XF, Shen XQ, Fisher CJ & Shemshedini L 2000 c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine 13 55-62. (doi:10.1385/ENDO:13:1:55)
11. Bubulya A, Chen SY, Fisher CJ, Zheng Z, Shen XQ & Shemshedini L 2001 c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. Journal of Biological Chemistry 276 44704-44711. (doi:10.1074/jbc.M107346200)
12. Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, Bearss D & Nagle RB 2005 Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate 64 341-346. (doi:10.1002/pros.20247)
13. Cen B, Mahajan S, Wang W & Kraft AS 2013 Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Research 73 3402-3411. (doi:10.1158/0008-5472. CAN-12-4619)
14. Chao SH & Price DH 2001 Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. Journal of Biological Chemistry 276 31793-31799. (doi:10.1074/jbc.M102306200)
15. Chen S, Xu Y, Yuan X, Bubley GJ & Balk SP 2006 Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. PNAS 103 15969-74. (doi:10.1073/pnas.0604193103)
16. Chen S, Gulla S, Cai C & Balk SP 2012 Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. Journal of Biological Chemistry 287 8571-8583. (doi:10.1074/jbc.M111.325290)
17. Chi Y, Zhang C, Zong H, Hong Y, Kong X, Liu H, Zou W, Wang Y, Yun X & Gu J 2011 Thr-370 is responsible for CDK11(p58) autophosphorylation, dimerization, and kinase activity. Journal of Biological Chemistry 286 1748-1757. (doi:10.1074/jbc.M110.107367)
18. Chymkowitch P, Le May N, Charneau P, Compe E & Egly JM 2011 The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO Journal 30 468-479. (doi:10.1038/emboj.2010. 337)
19. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A et al. 2003 The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. American Journal of Pathology 162 233-241. (doi:10.1016/S0002-9440(10)63814-X)
20. Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, Li W, Guo Z, Xu K, Kim O et al. 2010 Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Research 70 5587-5596. (doi:10.1158/0008-5472.CAN-09-4610)
21. DaSilva J, Gioeli D, Weber MJ & Parsons SJ 2009 The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Research 69 7402-7411. (doi:10.1158/0008-5472.CAN-08-4687)
22. Dhavan R & Tsai LH 2001 A decade of CDK5. Nature Reviews. Molecular Cell Biology 2 749-759. (doi:10.1038/35096019)
23. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO & Trapman J 1997 Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36 1052-1064. (doi:10.1021/bi961775g)
24. Fronsdal K, Engedal N, Slagsvold T & Saatcioglu F 1998 CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. Journal of Biological Chemistry 273 31853-31859. (doi:10.1074/jbc.273.48. 31853)
25. Furukawa J, Miyake H, Takenaka A, Hara I & Fujisawa M 2007 Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. BJU International 100 310-314. (doi:10.1111/j.1464-410X.2007.06982.x)
26. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015. (doi:10.1200/JCO.2002.10.018)
27. Gioeli D & Paschal BM 2012 Post-translational modification of the androgen receptor. Molecular and Cellular Endocrinology 352 70-78. (doi:10.1016/j.mce.2011.07.004)
28. Gioeli D, Mandell JW, Petroni GR, Frierson HF & Weber MJ 1999 Activation of mitogen-activated protein kinase aassociated with prostate cancer progression. Cancer Research 59 279-284. (Pubitemid 29048852)
29. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J et al. 2002 Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. Journal of Biological Chemistry 277 29304-29314. (doi:10.1074/jbc.M204131200)
30. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM & Weber MJ 2006 Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Molecular Endocrinology 20 503-515. (doi:10.1210/me.2005-0351)
31. Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF III, Conaway M & Weber MJ 2011 Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Molecular Cancer Therapeutics 10 1581-1590. (doi:10.1158/1535-7163. MCT-10-1033)
32. Gordon V, Bhadel S, Wunderlich W, Zhang J, Ficarro SB, Mollah SA, Shabanowitz J, Hunt DF, Xenarios I, Hahn WC et al. 2010 CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Molecular Endocrinology 24 2267-2280. (doi:10.1210/me.2010-0238)
33. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS & Wilson EM 2004 Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. Journal of Biological Chemistry 279 7119-7130. (doi:10.1074/jbc.M307649200)
34. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD et al. 2006 Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 309-319. (doi:10.1016/j.ccr.2006.08.021)
35. Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J & Garabedian MJ 2012 Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene 32 3992-4000. (doi:10.1038/onc.2012.412)
36. Harper JW & Elledge SJ 1998 The role of Cdk7 in CAK function, a retro-retrospective. Genes and Development 12 285-289. (doi:10.1101/gad.12.3. 285)
37. He B, Bai S, Hnat AT, Kalman RI, Minges JT, Patterson C & Wilson EM 2004 An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). Journal of Biological Chemistry 279 30643-30653. (doi:10.1074/jbc.M403117200)
38. Heemers HV & Tindall DJ 2007 Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrine Reviews 28 778-808. (doi:10.1210/er.2007-0019)
39. Heinlein CA & Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocrine Reviews 23 175-200. (Pubitemid 34299023)
40. Hickey TE, Robinson JLL, Carroll JS & Tilley WD 2012 Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Molecular Endocrinology 26 1252-1267. (doi:10.1210/me.2012-1107)
41. Hsu F-N, Chen M-C, Chiang M-C, Lin E, Lee Y-T, Huang P-H, Lee G-S & Lin H 2011 Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. Journal of Biological Chemistry 286 33141-33149. (doi:10.1074/jbc.M111.252080)
42. Hübner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, Chi H, Greiner DL, Tournier C, Sawyers CL et al. 2012 JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. PNAS 109 12046-12051. (doi:10.1073/pnas.1209660109)
43. Kasina S & Macoska JA 2012 The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Molecular and Cellular Endocrinology 351 249-263. (doi:10.1016/j.mce.2011.12.015)
44. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C et al. 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation 118 3051-3064. (doi:10.1172/JCI34764)
45. Kotaja N, Karvonen U, Janne OA & Palvimo JJ 2002a The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. Journal of Biological Chemistry 277 30283-30288. (doi:10.1074/jbc. M204768200)
46. Kotaja N, Karvonen U, Janne OA & Palvimo JJ 2002b PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Molecular and Cellular Biology 22 5222-5234. (doi:10.1128/MCB.22.14.5222-5234.2002)
47. Lagarde WH, Blackwelder AJ, Minges JT, Hnat AT, French FS & Wilson EM 2012 Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation. Journal of Biological Chemistry 287 10905-10915. (doi:10.1074/jbc.M111.336081)
48. Langley E, Zhou ZX & Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. Journal of Biological Chemistry 270 29983-29990. (doi:10.1074/jbc.270.10.5251)
49. Lin HK, Yeh S, Kang HY & Chang C 2001 Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 98 7200-7205. (doi:10.1073/pnas.121173298)
50. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY & Chang C 2003 Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. Journal of Biological Chemistry 278 50902-50907. (doi:10.1074/jbc.M300676200)
51. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555. (Pubitemid 32694958)
52. Linn DE, Yang X, Xie Y, Alfano A, Deshmukh D, Wang X, Shimelis H, Chen H, Li W, Xu K et al. 2012 Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. Journal of Biological Chemistry 287 22959-22968. (doi:10.1074/jbc.M111. 338350)
53. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS & Whang YE 2010 Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 29 3208-3216. (doi:10.1038/onc.2010.103)
54. Liu T, Li Y, Gu H, Zhu G, Li J, Cao L & Li F 2013 p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2). Journal of Biological Chemistry 288 3359-3369. (doi:10.1074/jbc.M112.384289)
55. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS & Wilson EM 1988 Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240 327-330. (doi:10.1126/science.3353727)
56. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS & Whang YE 2007 Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. PNAS 104 8438-8443. (doi:10.1073/pnas.0700420104)
57. Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ & Mahajan NP 2010 Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 70 1274-1285. (doi:10.1002/pros.21163)
58. Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, Lawrence NJ & Mahajan NP 2012 Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. Journal of Biological Chemistry 287 22112-22122. (doi:10.1074/jbc.M112. 357384)
59. Malumbres M & Barbacid M 2009 Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews. Cancer 9 153-166. (doi:10.1038/nrc2602)
60. Mandell JW, Hussaini IM, Zecevic M, Weber MJ & VandenBerg SR 1998 In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. American Journal of Pathology 153 1411-1423. (doi:10.1016/S0002-9440(10)65728-8)
61. McCall P, Gemmell LK, Mukherjee R, Bartlett JM & Edwards J 2008 Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. British Journal of Cancer 98 1094-1101. (doi:10.1038/sj.bjc.6604152)
62. McCall P, Adams CE, Willder JM, Bennett L, Qayyum T, Orange C, Underwood MA & Edwards J 2013 Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients. International Journal of Molecular Sciences 14 16656-16671. (doi:10.3390/ijms140816656)
63. McKenna NJ & O'Malley BW 2002a Minireview: nuclear receptor coactivators - an update. Endocrinology 143 2461-2465. (Pubitemid 34701305)
64. McKenna NJ & O'Malley BW 2002b Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 465-474. (doi:10.1016/S0092-8674(02)00641-4)
65. McNally JG, Müller WG, Walker D, Wolford R & Hager GL 2000 The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 287 1262-1265. (doi:10.1126/science.287.5456.1262)
66. Mellinghoff IK, Tran C & Sawyers CL 2002 Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Research 62 5254-5259. (Pubitemid 35024599)
67. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R et al. 2013 Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15 1-10.
68. Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G & Klocker H 2000 Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culturemodels. Prostate 45 124-131. (doi:10.1002/1097-0045(20001001)45:2<124::AID-PROS6<3.0.CO;2-7)
69. Olshavsky NA, Groh EM, Comstock CE, Morey LM, Wang Y, Revelo MP, Burd C, Meller J & Knudsen KE 2008 Cyclin D3 action in androgen receptor regulation and prostate cancer. Oncogene 27 3111-3121. (doi:10.1038/sj.onc.1210981)
70. Palazzolo I, Burnett BG, Young JE, Brenne PL, La Spada AR, Fischbeck KH, Howell BW & Pennuto M 2007 Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics 16 1593-1603. (doi:10.1093/hmg/ddm109)
71. Ponguta LA, Gregory CW, French FS & Wilson EM 2008 Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. Journal of Biological Chemistry 283 20989-21001. (doi:10.1074/jbc.M802392200)
72. Ren Q, Zhang L, Ruoff R, Ha S, Wang J, Jain S, Reuter V, Gerald W, Giri DD, Melamed J et al. 2013 Expression of androgen receptor and its phosphorylated forms in breast cancer progression. Cancer 119 2532-2540. (doi:10.1002/cncr. 28092)
73. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ & Pestell RG 2001 Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Molecular Endocrinology 15 797-811. (Pubitemid 32411317)
74. Rocha J, Zouanat F, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A & Chevalier S 2013 The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Molecular and Cellular Endocrinology 381 140-9. (doi:10.1016/j.mce.2013.07.017)
75. Saris CJ, Domen J & Berns A 1991 The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO Journal 10 655-664. (Pubitemid 21905520)
76. Sarker D, Reid A, Yap T & de Bono JS 2009 Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clinical Cancer Research 15 4799-4805. (doi:10.1158/1078-0432.CCR-08-0125)
77. Shah N, Pang B, Yeoh K-G, Thorn S, Chen CS, Lilly MB & Salto-Tellez M 2008 Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. European Journal of Cancer 44 2144-2151. (doi:10.1016/j.ejca.2008.06.044)
78. Shen MM & Abate-Shen C 2007 Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Research 67 6535-6538. (doi:10.1158/0008-5472.CAN-07-1271)
79. Shu SK, Liu Q, Coppola D & Cheng JQ 2010 Phosphorylation and activation of androgen receptor by Aurora-A. Journal of Biological Chemistry 285 33045-33053. (doi:10.1074/jbc.M110.121129)
80. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan S-H, Vaidyanathan G, Whitman E et al. 2008 TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27 5348-5353. (doi:10.1038/onc.2008.183)
81. Taneja SS, Ha S, Swenson NK, Huang HY, Lee P, Melamed J, Shapiro E, Garabedian MJ & Logan SK 2005 Cell-specific regulation of androgen receptor phosphorylation in vivo. Journal of Biological Chemistry 280 40916-40924. (doi:10.1074/jbc.M508442200)
82. Tillman K, Oberfield JL, Shen XQ, Bubulya A & Shemshedini L 1998 c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation. Endocrine 9 193-200. (doi:10.1385/ENDO:9:2:193)
83. Varisli L, Gonen-Korkmaz C, Syed HM, Bogurcu N, Debelec-Butuner B, Erbaykent-Tepedelen B & Korkmaz KS 2012 Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells. Molecular and Cellular Endocrinology 350 107-117. (doi:10.1016/j.mce.2011.11.027)
84. Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y & Chang C 2001 Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. Journal of Biological Chemistry 276 40417-40423. (doi:10.1074/jbc.M104765200)
85. Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML & Abdulkadir SA 2010 Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29 2477-2487. (doi:10.1038/onc.2010.10)
86. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH & Hung MC 2000 HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research 60 6841-6845. (Pubitemid 32059149)
87. Willder JM, Heng SJ, McCall P, Adams CE, Tannahill C, Fyffe G, Seywright M, Horgan PG, Leung HY, Underwood MA et al. 2013 Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. British Journal of Cancer 108 139-148. (doi:10.1038/bjc.2012. 480)
88. Wise SC, Burmeister LA, Zhou XF, Bubulya A, Oberfield JL, Birrer MJ & Shemshedini L 1998 Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene 16 2001-2009. (doi:10.1038/sj.onc.1201697)
89. Wood NT, Meek DW & Mackintosh C 2009 14-3-3 Binding to Pim-phosphorylated Ser166 and Ser186 of human Mdm2 - potential interplay with the PKB/Akt pathway and p14(ARF). FEBS Letters 583 615-620. (doi:10.1016/j. febslet.2009.01.003)
90. Wu K, Liu J, Tseng S-F, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G et al. 2014 The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 33 1954-1963. (doi:10.1038/onc. 2013.143)
91. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Kong X et al. 2009 Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15 270-282. (doi:10.1016/j.ccr.2009.02.021)
92. Yang CS, Xin HW, Kelley JB, Spencer A, Brautigan DL & Paschal BM 2007 Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Molecular and Cellular Biology 27 3390-3404. (doi:10.1128/MCB.02411-06)
93. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF & Chang C 1999 From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96 5458-5463. (doi:10.1073/pnas.96.10.5458)
94. Zellweger T, Stürm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, Terracciano LM, Bachmann A, Bubendorf L & Ruiz C 2013 Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocrine-Related Cancer 20 403-413. (doi:10.1530/ERC-12-0402)
95. Zhang Y, Wang Z, Li X & Magnuson NS 2008 Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27 4809-4819. (doi:10.1038/onc.2008. 123)
96. Zippo A, De Robertis A, Serafini R & Oliviero S 2007 PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nature Cell Biology 9 932-944. (doi:10.1038/ncb1618)
97. Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, Jiang J, Li Z, Hong Y, Wang H et al. 2007 Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Molecular and Cellular Biology 27 7125-7142. (doi:10.1128/MCB.01753-06)